{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:44:02Z","timestamp":1777016642540,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001870","name":"Fundacja na rzecz Nauki Polskiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO-2022\/45\/B\/NZ7\/00598"],"award-info":[{"award-number":["UMO-2022\/45\/B\/NZ7\/00598"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118728","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T19:39:22Z","timestamp":1762025962000},"page":"118728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel hybrid pyrrolidin-2-one derivatives exhibiting potent antiseizure and antinociceptive effects in preclinical models"],"prefix":"10.1016","volume":"193","author":[{"given":"Marcin","family":"Jakubiec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Abram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0079-0490","authenticated-orcid":false,"given":"Miros\u0142aw","family":"Zagaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7706-2080","authenticated-orcid":false,"given":"Katarzyna","family":"Soca\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanja","family":"Panic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gniewomir","family":"Latacz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szczepan","family":"Mogilski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Szafarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8013-3361","authenticated-orcid":false,"given":"Aleksandra","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5774-5180","authenticated-orcid":false,"given":"Peter J.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Przejczowska-Pomierny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"Stasiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7913-9092","authenticated-orcid":false,"given":"Jakub","family":"S\u0142ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Jasi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czopek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4798-0574","authenticated-orcid":false,"given":"El\u017cbieta","family":"Wyska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-0241","authenticated-orcid":false,"given":"Piotr","family":"Wla\u017a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron S.","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Andres-Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118728_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118728_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00301","article-title":"Drug-resistant epilepsy: multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.biopha.2025.118728_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.730257","article-title":"Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy","volume":"12","author":"L\u00f6scher","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118728_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118728_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejmech.2014.01.060","article-title":"Multifunctional compounds: smart molecules for multifactorial diseases","volume":"76","author":"Bansal","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1353-8020(13)70032-4","article-title":"Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson\u2019s disease","volume":"20","author":"Youdim","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.biopha.2025.118728_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1570159X1203140511153200","article-title":"Multi-target directed drugs: a modern approach for design of new drugs for the treatment of alzheimer\u2019s disease","volume":"12","author":"Simone","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118728_bib8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1017\/S1461145712001496","article-title":"On \u2018polypharmacy\u2019 and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal","volume":"17","author":"Millan","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2025.118728_bib9","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2174\/0929867311320130013","article-title":"Rationally designed multitarget agents against inflammation and pain","volume":"20","author":"Hwang","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2174\/1568026616666160927155515","article-title":"Hybrid compounds as multitarget directed anticancer agents","volume":"17","author":"Kucuksayan","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/14656560902781907","article-title":"Multitarget drugs: the present and the future of cancer therapy","volume":"10","author":"Petrelli","year":"2009","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.biopha.2025.118728_bib12","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2025.118728_bib13","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single drug: multitarget drugs","volume":"20","author":"L. Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib14","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12264-023-01138-2","article-title":"Development of SV2a ligands for epilepsy treatment: a review of levetiracetam, brivaracetam, and padsevonil","volume":"40","author":"Wu","year":"2024","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.biopha.2025.118728_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nurt.2006.11.014","article-title":"Seletracetam (UCB 44212)","volume":"4","author":"Bennett","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopha.2025.118728_bib17","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acschemneuro.0c00257","article-title":"Multitargeted compounds derived from (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamides as candidates for effective anticonvulsant and antinociceptive agents","volume":"11","author":"Abram","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2025.118728_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121862","article-title":"New phenylglycinamide derivatives with hybrid structure as candidates for new broad-spectrum anticonvulsants","volume":"11","author":"Jakubiec","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118728_bib19","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/epi.16669","article-title":"KA-104, a new multitargeted anticonvulsant with potent antinociceptive activity in preclinical models","volume":"61","author":"Kami\u0144ski","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2025.118728_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/01616412.2022.2143617","article-title":"Levetiracetam treatment in an experimental model of sciatic nerve injury: A randomized controlled trial","volume":"45","author":"Apaydin","year":"2023","journal-title":"Neurol. Res."},{"key":"10.1016\/j.biopha.2025.118728_bib21","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.4103\/0028-3886.193801","article-title":"Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug","volume":"64","author":"Cortes-Altamirano","year":"2016","journal-title":"Neurol. India"},{"key":"10.1016\/j.biopha.2025.118728_bib22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1476-5381.2010.00877.x","article-title":"The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: mechanism of action","volume":"161","author":"Micov","year":"2010","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118728_bib23","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1213\/ANE.0b013e31826c7fc2","article-title":"The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model","volume":"115","author":"Stepanovic-Petrovic","year":"2012","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.biopha.2025.118728_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113728","article-title":"Modulation of nociception and pain-evoked neurobehavioral responses by levetiracetam in a craniotomy pain model","volume":"420","author":"Tsaousi","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2025.118728_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.phrs.2015.04.014","article-title":"Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropath\u201d","volume":"97","author":"Micov","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2025.118728_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfp097","article-title":"Chiral toxicology: it\u2019s the same thingonly different","volume":"110","author":"Smith","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biopha.2025.118728_bib27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2174\/156802611795165098","article-title":"The significance of chirality in drug design and development","volume":"11","author":"Brooks","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fitote.2015.05.020","article-title":"Effect of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of classical antiepileptic drugs against maximal electroshock-induced seizures in mice","volume":"105","author":"Zagaja","year":"2015","journal-title":"Fitoterapia"},{"key":"10.1016\/j.biopha.2025.118728_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s13311-019-00773-w","article-title":"N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug","volume":"17","author":"Kami\u0144ski","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopha.2025.118728_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183873","article-title":"Effects of arachidonyl-2\u2019-chloroethylamide (ACEA) on the protective action of various antiepileptic drugs in the 6-Hz corneal stimulation model in mice","volume":"12","author":"Luszczki","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2025.118728_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.biopha.2025.118728_bib32","first-page":"81","article-title":"Une nouvelle m\u00e9thode simple pour explorer l\u2019action \u00abtranquillisante\u00bb: le test de la chemin\u00e9e","volume":"3","author":"Boissier","year":"1960","journal-title":"PHA"},{"key":"10.1016\/j.biopha.2025.118728_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.04.010","article-title":"Increased seizure susceptibility and other toxicity symptoms following acute sulforaphane treatment in mice","volume":"326","author":"Soca\u0142a","year":"2017","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.biopha.2025.118728_bib34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/acschemneuro.8b00476","article-title":"KA-11, a Novel Pyrrolidine-2,5-dione Derived Broad-Spectrum Anticonvulsant: Its Antiepileptogenic, Antinociceptive Properties and in Vitro Characterization","volume":"10","author":"Soca\u0142a","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2025.118728_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbr.2016.01.048","article-title":"Evaluation of the antidepressant- and anxiolytic-like activity of \u03b1-spinasterol, a plant derivative with TRPV1 antagonistic effects, in mice","volume":"303","author":"Soca\u0142a","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2025.118728_bib36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0014-2999(98)00026-0","article-title":"Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action","volume":"345","author":"Beirith","year":"1998","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118728_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pbb.2015.03.019","article-title":"Antinociceptive, anti-inflammatory and smooth muscle relaxant activities of the pyrrolo[3,4-d]pyridazinone derivatives: Possible mechanisms of action","volume":"133","author":"Mogilski","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.biopha.2025.118728_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Sa\u0142at","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.biopha.2025.118728_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpz1.78","article-title":"Streptozotocin-Induced Diabetic Models in Mice and Rats","volume":"1","author":"Furman","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.biopha.2025.118728_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00011-016-0997-z","article-title":"Aryl-1,3,5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide","volume":"66","author":"Mogilski","year":"2017","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.biopha.2025.118728_bib41","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/epi.14563","article-title":"Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs","volume":"59","author":"West","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2025.118728_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313092","article-title":"Identification of New Compounds with Anticonvulsant and Antinociceptive Properties in a Group of 3-substituted (2,5-dioxo-pyrrolidin-1-yl)(phenyl)-Acetamides","volume":"22","author":"Abram","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118728_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143420","article-title":"The 1,3,5-triazine derivatives as innovative chemical family of 5-HT6 serotonin receptor agents with therapeutic perspectives for cognitive impairment","volume":"20","author":"Latacz","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118728_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejmech.2019.06.022","article-title":"Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6","volume":"178","author":"Ali","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24244472","article-title":"Are the hydantoin-1,3,5-triazine 5-ht6r ligands a hope to a find new procognitive and anti-obesity drug? considerations based on primary in vivo assays and adme-tox profile in vitro","volume":"24","author":"Lubelska","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118728_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2025.118728_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107750","article-title":"Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening","volume":"167","author":"Barker-Haliski","year":"2020","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.biopha.2025.118728_bib48","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1007\/s11064-017-2275-z","article-title":"The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)","volume":"42","author":"Kehne","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.biopha.2025.118728_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.biopha.2025.118728_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2025.118728_bib51","series-title":"Red., Neuropharmacology methods in epilepsy research. in CRC Press methods in the life sciences Cellular and molecular neuropharmacology","author":"Peterson","year":"1988"},{"key":"10.1016\/j.biopha.2025.118728_bib52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11064-023-04064-x","article-title":"The Possible Role of Brain-derived Neurotrophic Factor in Epilepsy","volume":"49","author":"AlRuwaili","year":"2024","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.biopha.2025.118728_bib53","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1523\/JNEUROSCI.17-14-05288.1997","article-title":"Nerve Growth Factor Accelerates Seizure Development, Enhances Mossy Fiber Sprouting, and Attenuates Seizure-Induced Decreases in Neuronal Density in the Kindling Model of Epilepsy","volume":"17","author":"Adams","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118728_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107474","article-title":"Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis","volume":"208","author":"Garami","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118728_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/j.pain.0000000000000441","article-title":"Cell transplants to treat the \u201cdisease\u201d of neuropathic pain and itch","volume":"157","author":"Basbaum","year":"2016","journal-title":"PAIN"},{"key":"10.1016\/j.biopha.2025.118728_bib56","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1021\/acs.jmedchem.7b01114","article-title":"Multifunctional hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)-3-methoxypropanamides with anticonvulsant and antinociceptive properties","volume":"60","author":"Abram","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118728_bib57","first-page":"936","article-title":"Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists","volume":"37","author":"Tabrizi","year":"2017","journal-title":"Med. Res. Res."},{"key":"10.1016\/j.biopha.2025.118728_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2024.102634","article-title":"TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates","volume":"240","author":"Soca\u0142a","year":"2024","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118728_bib59","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acschemneuro.4c00438","article-title":"Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates","volume":"15","author":"Jakubiec","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2025.118728_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.2016.1121097","article-title":"The possible use of the L-type calcium channel antagonist verapamil in drug-resistant epilepsy","volume":"16","author":"Nicita","year":"2016","journal-title":"Exp. Rev. Neurother."},{"key":"10.1016\/j.biopha.2025.118728_bib61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brainresrev.2009.12.005","article-title":"Voltage-gated calcium channels in the etiopathogenesis and treatment of absence epilepsy","volume":"62","author":"Weiergr\u00e4ber","year":"2010","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.biopha.2025.118728_bib62","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022814","article-title":"Role of Sodium Channels in Epilepsy","volume":"6","author":"Kaplan","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2025.118728_bib63","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/bph.13747","article-title":"Calcium signalling through L-type calcium channels: role in pathophysiology of spinal nociceptive transmission","volume":"175","author":"Roca-Lapirot","year":"2018","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118728_bib64","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1113\/JP272725","article-title":"Cav1.2 and Cav1.3 L-type calcium channels independently control short- and long-term sensitization to pain","volume":"594","author":"Radwani","year":"2016","journal-title":"J. Physiol."},{"key":"10.1016\/j.biopha.2025.118728_bib65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13543784.2020.1728254","article-title":"Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers","volume":"29","author":"Kushnarev","year":"2020","journal-title":"Expert Opin. Inv. Drugs"},{"key":"10.1016\/j.biopha.2025.118728_bib66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0959-4388(03)00074-6","article-title":"The role of voltage-gated sodium channels in neuropathic pain","volume":"13","author":"Lai","year":"2003","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118728_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.biopha.2025.118728_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ph15040475","article-title":"Levetiracetam Mechanisms of Action: From Molecules to Systems","volume":"15","author":"Contreras-Garc\u00eda","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118728_bib69","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s11064-009-9912-0","article-title":"Role of Glutamate and GABA Transporters in Development of Pentylenetetrazol-Kindling","volume":"34","author":"Doi","year":"2009","journal-title":"Neurochem. Res"},{"key":"10.1016\/j.biopha.2025.118728_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/cells12091233","article-title":"Animal Models of Drug-Resistant Epilepsy as Tools for Deciphering the Cellular and Molecular Mechanisms of Pharmacoresistance and Discovering More Effective Treatments","volume":"12","author":"L\u00f6scher","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118728_bib71","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2174\/1381612054021006","article-title":"Ion Channels and Epilepsy","volume":"11","author":"Armijo","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2025.118728_bib72","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1212\/WNL.0000000000001382","article-title":"Ion channels in nociceptors","volume":"84","author":"Benarroch","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2025.118728_bib73","series-title":"100 Years of the Handbook of Experimental Pharmacology, J. E. Barrett, C. P. Page, I M. C. Michel, Red","first-page":"161","article-title":"Ion Channel Pharmacology for Pain Modulation, in Concepts and Principles of Pharmacology","author":"De Logu","year":"2019"},{"key":"10.1016\/j.biopha.2025.118728_bib74","article-title":"Transient Receptor Potential (TRP) Channels in Pain, Neuropsychiatric Disorders, and Epilepsy","volume":"24","author":"Yang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118728_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112618","article-title":"Recent Progress in TRPM8 modulation: an update","volume":"20","author":"Gonz\u00e1lez-Mu\u00f1iz","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118728_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1334370","article-title":"Targeting TRP channels: recent advances in structure, ligand binding, and molecular mechanisms","volume":"16","author":"Huang","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2025.118728_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-021-00268-4","article-title":"Advances in TRP channel drug discovery: from target validation to clinical studies","volume":"21","author":"Koivisto","year":"2022","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:09:47Z","timestamp":1777014587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":77,"alternative-id":["S0753332225009229"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118728","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel hybrid pyrrolidin-2-one derivatives exhibiting potent antiseizure and antinociceptive effects in preclinical models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118728"}}